NCT00040573View on ClinicalTrials.gov

Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2002

Study Completion Date

August 31, 2003

Conditions
GliomaBrain Neoplasm
Interventions
DRUG

131I-TM-601

Trial Locations (3)

35294-3295

University of Alabama at Birmingham, Birmingham

91010-3000

City of Hope, Duarte

63110-0250

Saint Louis University, St Louis

Sponsors

Lead Sponsor

TransMolecular
All Listed Sponsors
lead

TransMolecular

INDUSTRY

NCT00040573 - Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma. | Biotech Hunter | Biotech Hunter